Table 1.
Summary of recent NK cell adoptive therapy clinical trials. Flu, intravenous fludarabine; Cy,intravenous cyclophosphamide; IL2DT, IL-2-diphtheria fusion protein; A, Adult; P, Pediatric; CD3−, CD3 depletion; CD56+, CD56, positive selection; CD19−, CD19 depletion; NR, not reported. CR rates include those patients with active disease at the time of therapy.
| Study | Conditioning | Post-Infusion Therapy IL-2 (×106 IU/m2) |
KIR-KIR ligand Mismatch |
Purification | NK Dose (× 106/kg) |
Donor Chimerism |
Donor NK cell number (per μl) |
Peak Expansion (Days) |
CR | GVHD | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Rubnitz et
al., 2010 |
Flu-Cy | 1.0 | Yes | CD3-CD56+ | 29 | 7 % (NK) | 5.8 | 14 | NA | No | [13] |
|
Curti et al.,
2011 |
Flu-Cy | 1.0 | Yes | CD3-CD56+ | 2.5 | NR | NR | 7-10 | 1/5 | No | [14] |
|
Miller et al.,
2005 |
Flu-Cy | 1.75-10 | No | CD3- | 9 | 25 % (PBMC) | NR | 14 | 5/19 | No | [15] |
|
Bachanova
et al., 2014 |
Flu-Cy | 9.0 | 7 | [16] | |||||||
| Cohort 1 | 17% | CD3- | 9.6 | NR | NR | 5/19 | No | ||||
| Cohort 2 | 50% | CD3-CD56+ | 3.4 | NR | NR | No | |||||
| Cohort 3 | +IL2DT | 56% | CD3-CD19− | 26 | 49 % (PBMC) | 190 | 8/15 | No |